Here are the S-1 registration statements from SeaStar Medical Holding Corporation Warrant (ICUCW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow ICUCW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICUCW filings page.
SeaStar Medical Holding Corporation is filing an S-1 to register the resale of up to 1,664,543 shares of common stock held by Lincoln Park Capital Fund LLC. These shares relate to a previously signed $15.0 million equity purchase agreement, under which SeaStar can periodically sell stock to Lincoln Park.
SeaStar will not receive proceeds from Lincoln Park’s resale of these registered shares, but may receive up to an additional $14,657,887.43 in gross proceeds from future share sales to Lincoln Park under the agreement. As of April 20, 2026, the company had 3,997,002 shares outstanding, and sales under this structure, alongside past at-the-market offerings, could dilute existing holders.
The filing also describes SeaStar’s commercial-stage inflammatory disease platform, including its FDA-approved pediatric SCD therapy under a Humanitarian Device Exemption, multiple Breakthrough Device Designations, and ongoing adult clinical programs targeting acute kidney injury and cardiorenal indications.